From: Choroidal bulging in patients with Vogt-Koyanagi-Harada disease in the non-acute uveitic stage
Patient, gender, age (years) | Studied eye | Disease duration (months) | Choroidal bulging | Signs of disease activity | Changes observed at subsequent FU visit | ||||
---|---|---|---|---|---|---|---|---|---|
Location | Change | ACC | Hyperfluorescence of OD on FA | Dark dots on ICGA | Medication adjustment after CB visit | ||||
1, M, 65 | RE | 117 | Outer nasal | +139 μm (+74%) | +/2 | − | + | None | Month 137: improvement of CB (−145 μm), increase in ACC (+), absence of dark dots (−) |
2, F, 54 | RE | 10 | Outer nasal | +131 μm (+139%) | + | ++ | +++ | Tapering of oral prednisone (15 to 10 mg/day) | Month 17: worsening of CB (+66 μm), increase in OD hyperfluorescence (+++), localized increase of dark dots |
LE | 10 | Outer nasal | +138 μm (+107%) | + | ++ | +++ | Month 17: improvement of CB (−101 μm), decrease in OD hyperfluorescence (+/2), decrease of dark dots (+) | ||
3, F, 53 | LE | 32 | Parafoveal | +215 μm (+74%) | + | + | ++ | Substitution for mycophenolate mofetil 1.5 g/day | Month 35: disappearance of CB (−74 μm), maintenance in OD hyperfluorescence (+), attenuation of dark dots |